评估含有羟氯喹和阿奇霉素的 COVID-19 治疗方法：一项自然临床研究。
Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial.
机构信息
Headquarter, Ministry of Health, Baghdad, Iraq.
College of Pharmacy, University of Iowa, Iowa City, IA, USA.
出版信息
Int J Clin Pract. 2021 Apr;75(4):e13856. doi: 10.1111/ijcp.13856. Epub 2020 Dec 5.
UNLABELLED
The goal of this study was to assess the clinical effectiveness and safety profile of the COVID-19 treatment protocol (containing both hydroxychloroquine (HCQ) and azithromycin) in an Iraqi specialised hospital.
METHODS
This prospective study used a pre- and post-intervention design without a comparison group. The intervention was routine Ministry of Health (MOH) approved the management of COVID-19 for all patients. The study was conducted in a public healthcare setting in Baghdad, Iraq from March 1st to May 25, 2020. The study outcome measures included the changes in clinical and biochemical parameters during the hospitalisation period. Paired t-test and Chi-square test were used to compare the measures of vital signs, lab tests and symptoms before and after treatment.
RESULTS
The study included 161 patients who were admitted with positive RT-PCR and clinical symptoms of COVID-19. In terms of severity, 53 (32.9%) patients had amild condition, 47 (29.2%) had moderate condition, 35 (21.7%) had severe condition and 26 (16.1%) had critical condition. Most patients (84.5%) recovered and were discharged without symptoms after testing negative with RT-PCR, while 11 (6.8%) patients died during the study period. The signs and symptoms of COVID-19 were reduced significantly in response to a therapy regimen containing HCQ and azithromycin. The most common reported side effects were stomach pain, hypoglycemia, dizziness, itching, skin rash, QT prolongation, arrhythmia, and conjunctivitis.
CONCLUSIONS
This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful.
未加标签
本研究旨在评估 COVID-19 治疗方案（包含羟氯喹和阿奇霉素）在伊拉克一家专科医院的临床疗效和安全性。
方法
这是一项前瞻性研究，采用前后对照设计，无对照组。干预措施为常规卫生部（MOH）批准的所有 COVID-19 患者的管理方案。该研究于 2020 年 3 月 1 日至 5 月 25 日在伊拉克巴格达的一家公共医疗保健机构进行。研究结果包括住院期间临床和生化参数的变化。采用配对 t 检验和卡方检验比较治疗前后生命体征、实验室检查和症状的变化。
结果
该研究纳入了 161 名经 RT-PCR 检测呈阳性且有 COVID-19 临床症状的患者。根据严重程度，53 例（32.9%）为轻症，47 例（29.2%）为中度，35 例（21.7%）为重症，26 例（16.1%）为危重症。大多数患者（84.5%）在检测 RT-PCR 结果阴性后无症状康复出院，11 例（6.8%）患者在研究期间死亡。含有羟氯喹和阿奇霉素的治疗方案可显著减轻 COVID-19 的症状和体征。最常见的不良反应报告为腹痛、低血糖、头晕、瘙痒、皮疹、QT 间期延长、心律失常和结膜炎。
结论
本自然试验表明，含有羟氯喹和阿奇霉素的 COVID-19 治疗方案有助于促进大多数患者康复，显著减轻其症状和体征。同时也表明存在一些可管理的不良反应，主要与心律有关。在缺乏 FDA 批准的 COVID-19 治疗药物的情况下，将羟氯喹和阿奇霉素重新用于控制疾病症状可能是有益的。
Zotero 插件